Industry
Biotechnology
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Loading...
Open
33.08
Mkt cap
1.7B
Volume
822K
High
33.75
P/E Ratio
-13.94
52-wk high
66.38
Low
29.93
Div yield
N/A
52-wk low
26.61
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 6:41 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:20 pm
Portfolio Pulse from Avi Kapoor
July 17, 2024 | 5:28 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 3:38 pm
Portfolio Pulse from Vandana Singh
July 17, 2024 | 2:47 pm
Portfolio Pulse from Avi Kapoor
July 17, 2024 | 12:21 pm
Portfolio Pulse from Benzinga Insights
July 15, 2024 | 3:15 pm
Portfolio Pulse from Benzinga Newsdesk
July 01, 2024 | 1:20 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 4:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.